150 related articles for article (PubMed ID: 29875309)
1. Repurposing sertraline sensitizes non-small cell lung cancer cells to erlotinib by inducing autophagy.
Jiang X; Lu W; Shen X; Wang Q; Lv J; Liu M; Cheng F; Zhao Z; Pang X
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875309
[TBL] [Abstract][Full Text] [Related]
2. LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells.
Whang YM; Park SI; Trenary IA; Egnatchik RA; Fessel JP; Kaufman JM; Carbone DP; Young JD
Oncogene; 2016 Feb; 35(7):856-66. PubMed ID: 26119936
[TBL] [Abstract][Full Text] [Related]
3. Repurposing of atorvastatin and metformin denotes their individual and combined antiproliferative effects in non-small cell lung cancer.
Salim EI; Elsebakhy S; Hessien M
Fundam Clin Pharmacol; 2024 Jun; 38(3):550-560. PubMed ID: 38258539
[TBL] [Abstract][Full Text] [Related]
4. Alpha-Hederin induces incomplete autophagic injury in non-small cell lung cancer by interfering with the lysosomal acidification.
Jin F; Jiang X; Ni X; Yu S; Wu F; Shi X; Mao D; Wang H; Shi Q; Liu Y; Xu Q
Sci Rep; 2024 Jun; 14(1):13258. PubMed ID: 38858422
[TBL] [Abstract][Full Text] [Related]
5. Engineering of Amphiphilic Erlotinib Analogue as Novel Nanomedicine for Non-Small Cell Lung Cancer Therapy.
Cong M; Pang H; Xie G; Li F; Li C; Sun H; Yang S; Zhao W
Int J Nanomedicine; 2023; 18():6367-6377. PubMed ID: 37954452
[TBL] [Abstract][Full Text] [Related]
6. 2-Aminoethoxydiphenylborane sensitizes anti-tumor effect of bortezomib via suppression of calcium-mediated autophagy.
Qu YQ; Gordillo-Martinez F; Law BYK; Han Y; Wu A; Zeng W; Lam WK; Ho C; Mok SWF; He HQ; Wong VKW; Wang R
Cell Death Dis; 2018 Mar; 9(3):361. PubMed ID: 29500417
[TBL] [Abstract][Full Text] [Related]
7. High-content analysis identified synergistic drug interactions between INK128, an mTOR inhibitor, and HDAC inhibitors in a non-small cell lung cancer cell line.
Wang S; Oliveira-Silveira J; Fang G; Kang J
BMC Cancer; 2024 Mar; 24(1):335. PubMed ID: 38475728
[TBL] [Abstract][Full Text] [Related]
8. Drug Repurposing in Non-Small Cell Lung Carcinoma: Old Solutions for New Problems.
Doumat G; Daher D; Zerdan MB; Nasra N; Bahmad HF; Recine M; Poppiti R
Curr Oncol; 2023 Jan; 30(1):704-719. PubMed ID: 36661704
[TBL] [Abstract][Full Text] [Related]
9. Transient Systemic Autophagy Inhibition Is Selectively and Irreversibly Deleterious to Lung Cancer.
Khayati K; Bhatt V; Lan T; Alogaili F; Wang W; Lopez E; Hu ZS; Gokhale S; Cassidy L; Narita M; Xie P; White E; Guo JY
Cancer Res; 2022 Dec; 82(23):4429-4443. PubMed ID: 36156071
[TBL] [Abstract][Full Text] [Related]
10. Excessive concentrations of kinase inhibitors in translational studies impede effective drug repurposing.
Liu C; Leighow SM; McIlroy K; Lu M; Dennis KA; Abello K; Brown DJ; Moore CJ; Shah A; Inam H; Rivera VM; Pritchard JR
Cell Rep Med; 2023 Oct; 4(10):101227. PubMed ID: 37852183
[TBL] [Abstract][Full Text] [Related]
11. Antidepressant Sertraline Hydrochloride Inhibits the Growth of HER2+ AU565 Breast Cancer Cell Line through Induction of Apoptosis and Cell Cycle Arrest.
Fayyaz S; Atia-Tul-Wahab ; Irshad R; Siddiqui RA; Iqbal Choudhary M
Anticancer Agents Med Chem; 2024 May; ():. PubMed ID: 38766835
[TBL] [Abstract][Full Text] [Related]
12. Targeting autophagy by antipsychotic phenothiazines: potential drug repurposing for cancer therapy.
Lopes RM; Souza ACS; Otręba M; Rzepecka-Stojko A; Tersariol ILS; Rodrigues T
Biochem Pharmacol; 2024 Apr; 222():116075. PubMed ID: 38395266
[TBL] [Abstract][Full Text] [Related]
13. The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity.
Holbeck SL; Camalier R; Crowell JA; Govindharajulu JP; Hollingshead M; Anderson LW; Polley E; Rubinstein L; Srivastava A; Wilsker D; Collins JM; Doroshow JH
Cancer Res; 2017 Jul; 77(13):3564-3576. PubMed ID: 28446463
[TBL] [Abstract][Full Text] [Related]
14. Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer.
Sánchez-Castillo A; Heylen E; Hounjet J; Savelkouls KG; Lieuwes NG; Biemans R; Dubois LJ; Reynders K; Rouschop KM; Vaes RDW; De Keersmaecker K; Lambrecht M; Hendriks LEL; De Ruysscher DKM; Vooijs M; Kampen KR
Br J Cancer; 2024 Mar; 130(4):568-584. PubMed ID: 38160212
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances of Autophagy in Non-Small Cell Lung Cancer: From Basic Mechanisms to Clinical Application.
Guo W; Du K; Luo S; Hu D
Front Oncol; 2022; 12():861959. PubMed ID: 35600411
[TBL] [Abstract][Full Text] [Related]
16. Novel Approach to Accelerate Lung Cancer Research: Lung-MAP and the Potential of Public-Private Partnerships.
Herbst RS; Blanke CD; Sigal EV
Clin Cancer Res; 2024 Jan; 30(1):29-32. PubMed ID: 37903180
[TBL] [Abstract][Full Text] [Related]
17. Decoding Serine Metabolism: Unveiling Novel Pathways for Evolving Cancer Therapies.
Lau A; Blenis J; Burgos-Barragan G
Cancer Res; 2024 Apr; 84(8):1191-1194. PubMed ID: 38364233
[TBL] [Abstract][Full Text] [Related]
18. Systems Biology and Cytokines Potential Role in Lung Cancer Immunotherapy Targeting Autophagic Axis.
Khilwani R; Singh S
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893079
[TBL] [Abstract][Full Text] [Related]
19. Erratum to Discovery of a Novel Potent Antitumor Molecule, P19G1, by Erlotinib Derivative.
Technol Cancer Res Treat; 2023; 22():15330338221149552. PubMed ID: 36632663
[No Abstract] [Full Text] [Related]
20. Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia.
Lago SG; Bahn S
ACS Chem Neurosci; 2019 Jan; 10(1):58-78. PubMed ID: 29944339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
